Takeda Pharmaceutical (TAK) EBIAT (2017 - 2025)
Historic EBIAT for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to $673.9 million.
- Takeda Pharmaceutical's EBIAT fell 949.08% to $673.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $8.7 billion, marking a year-over-year increase of 4445.08%. This contributed to the annual value of $709.9 million for FY2025, which is 2899.72% down from last year.
- Takeda Pharmaceutical's EBIAT amounted to $673.9 million in Q4 2025, which was down 949.08% from $4.7 billion recorded in Q3 2025.
- In the past 5 years, Takeda Pharmaceutical's EBIAT ranged from a high of $4.7 billion in Q3 2025 and a low of -$20.2 million during Q1 2024
- Moreover, its 5-year median value for EBIAT was $827.7 million (2022), whereas its average is $1.3 billion.
- As far as peak fluctuations go, Takeda Pharmaceutical's EBIAT crashed by 10254.51% in 2024, and later surged by 908369.57% in 2025.
- Takeda Pharmaceutical's EBIAT (Quarter) stood at $508.7 million in 2021, then surged by 65.8% to $843.4 million in 2022, then increased by 27.7% to $1.1 billion in 2023, then plummeted by 30.86% to $744.6 million in 2024, then dropped by 9.49% to $673.9 million in 2025.
- Its EBIAT stands at $673.9 million for Q4 2025, versus $4.7 billion for Q3 2025 and $1.5 billion for Q2 2025.